These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 18089452

  • 21. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
    Ouellet G, Cardinal H, Mailhot M, Ste-Marie LG, Roy L.
    Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
    [Abstract] [Full Text] [Related]

  • 22. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
    Negri AL.
    J Nephrol; 2010 Apr; 23(6):653-7. PubMed ID: 20349415
    [Abstract] [Full Text] [Related]

  • 23. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA, Galani VJ, Shah PR.
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
    Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S.
    Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L, Bernard LM, Elder GJ.
    Clin J Am Soc Nephrol; 2016 Feb 05; 11(2):232-44. PubMed ID: 26668024
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.
    Koiwa F, Onoda N, Kato H, Tokumoto A, Okada T, Fukagawa M, Shigematsu T, ROD 21 Clinical Research Group.
    Ther Apher Dial; 2005 Aug 05; 9(4):340-6. PubMed ID: 16076379
    [Abstract] [Full Text] [Related]

  • 31. Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study.
    Ruggeri M, Cipriani F, Bellasi A, Russo D, Di Iorio B.
    Blood Purif; 2014 Aug 05; 37(4):316-24. PubMed ID: 25171148
    [Abstract] [Full Text] [Related]

  • 32. Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data.
    St Peter WL, Fan Q, Weinhandl E, Liu J.
    Clin J Am Soc Nephrol; 2009 Dec 05; 4(12):1954-61. PubMed ID: 19833904
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
    Akizawa T, Origasa H, Kameoka C, Kaneko Y, Kawasaki S, Bixalomer Study Group.
    Ther Apher Dial; 2014 Apr 05; 18(2):122-31. PubMed ID: 24720402
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study.
    Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, Budoff M, CARE-2 Investigators.
    Am J Kidney Dis; 2008 Jun 05; 51(6):952-65. PubMed ID: 18423809
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients.
    Navaneethan SD, Palmer SC, Vecchio M, Craig JC, Elder GJ, Strippoli GF.
    Cochrane Database Syst Rev; 2011 Feb 16; (2):CD006023. PubMed ID: 21328279
    [Abstract] [Full Text] [Related]

  • 40. Chronic acid-base perturbations in hemodialysis patients treated with sevelamer hydrochloride: a two-year follow-up study.
    Vlahakos DV, Retsa K, Kalogeropoulou S, Katsoudas S, Bacharaki D, Agroyannis B.
    Artif Organs; 2007 Dec 16; 31(12):892-5. PubMed ID: 17924988
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.